Vestibular Migraine: What's the Impact?

News
Slideshow

Vestibular migraine may be a relatively new diagnostic entity, but a new study shows it impacts around 6 million US adults. 

Recent Videos
Primary Care is the Answer to the Migraine Care Gap, Says Headache Specialist
Migraine Management Pearls for Primary Care with Neurologist Jessica Ailani, MD
Migraine-specific therapies belong in primary care setting, Jessica Ailani, MD
Related Content
FDA Grants First-in-Class Marketing Authorization for Digital Therapeutic in Episodic Migraine Prevention

FDA Grants First-in-Class Marketing Authorization for Digital Therapeutic in Episodic Migraine Prevention

Grace Halsey
April 16th 2025
Article

CT-132 is a 12-week app-based intervention that uses validated behavioral techniques to modulate labile brain circuitry involved in migraine, according to Click Therapeutics.

Distress Signals: How to Help a Clinician Colleague in Need

Distress Signals: How to Help a Clinician Colleague in Need

Sydney Jennings
February 14th 2023
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Rebekah Bernard, MD, a family physician and national speaker on physician wellness.

Gantenerumab May Delay Alzheimer Disease Symptoms in High-Risk Adults: Daily Dose / image credit: ©New Africa/AdobeStock

Gantenerumab May Delay Alzheimer Disease Symptoms in High-Risk Adults: Daily Dose

Sydney Jennings
April 10th 2025
Article

Your daily dose of the clinical news you may have missed.

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Sydney Jennings
September 29th 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

Trontinemab: Roche Announces Phase 3 Development Program in Adults with Early Alzheimer Disease / image credit ©Sundry Photography

Trontinemab: Roche Announces Phase 3 Development Program for the mAb in Adults with Early Alzheimer Disease

Grace Halsey
April 7th 2025
Article

Using the proprietary Roche Brainshuttle technology, trontinemab leads to deep, rapid amyloid plaque reduction with a favorable safety profile.

For Sleep Disturbance in Alzheimer Disease, Cannabinoid-Based IGC-AD1 Shines in Phase 2

For Sleep Disturbance in Alzheimer Disease, Cannabinoid-Based IGC-AD1 Shines in Phase 2

Grace Halsey
March 27th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.